Pearsanta, a Subsidiary of ADiTx Inc., Invited to Submit Full Proposal for U.S. Defense Department's Ovarian Cancer Research Award
Reuters
Jul 24, 2025
Pearsanta, a Subsidiary of ADiTx Inc., Invited to Submit Full Proposal for U.S. Defense Department's Ovarian Cancer Research Award
Aditxt Inc.'s subsidiary, Pearsanta Inc., has been invited to submit a full proposal for the U.S. Department of Defense's Congressionally Directed Medical Research Program's Ovarian Cancer Research Program Pilot Award. This opportunity could support the development of the Mitomic® Ovarian Test (MOT™), a blood-based diagnostic for early detection of ovarian cancer. Pearsanta plans to validate the MOT™ at its Richmond, Virginia laboratory, aiming for a commercial launch as a laboratory-developed test. The project aligns with the program's goal to advance ovarian cancer diagnostics and treatment, potentially transforming standard care by enabling earlier detection through a simple blood test. If successful, it could significantly improve survival rates and quality of life for women diagnosed with ovarian cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724627121) on July 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.